Menu in lung cancer diagnostics

Accelerating the search in life-changing diagnostic decisions

Roche offers the comprehensive tissue diagnostics lung cancer portfolio – including the menu of companion diagnostics available – enabling **diagnosis and stratification** of lung cancer.

Comprehensive solutions in tissue diagnostics

40+

antibodies[1]

Continuous improvement

our lung cancer core menu and expanding our companion diagnostics menu and indications



Quality[4,5]

ALK IHC is able to run on small biopsies to predict tumor response and survival for patients with advanced NSCLC

Broad of assay menu

combining four key technologies: tissue diagnostics, immunoassays, molecular diagnostics and digital diagnostics

Reduce cost and make more immediate treatment decisions[2,3]

VENTANA® ALK (D5F3) CDx Assay was the IHC assay of choice for companion diagnostics, clinical trials, with no requirement of confirmation by FISH. VENTANA ROS1 (SP384) provides a cost-effective and efficient means of identifying cases with elevated ROS1 protein expression before confirming by another method, such as by FISH or NGS.

Roche PD-L1 CDx assay [6]

IVD testing is substantially for aligning PD-L1-positive NSCLC patients with immunotherapy – leading clinicians to make decisions for improved outcomes and a reduction in overall healthcare costs associated with disease progression, management of adverse events and end of life care.

[1] F. Hoffmann-La Roche Ltd. VENTANA Product Catalogue. [eLab Docs; cited 2024 August 21]. Data on file.
[2] Paolini, et al. "VENTANA ALK (D5F3) in the detection of patients affected by anaplastic lymphoma kinase-positive non small-cell lung cancer: clinical and budget effect". Clinical Lung Cancer, May 2018.
[3] Makarem M, et al. Reflex ROS1 IHC Screening with FISH Confirmation for Advanced Non-Small Cell Lung Cancer-A Cost-Efficient Strategy in a Public Healthcare System. Current Oncology, October 2021.
[4] Peters S, et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer. N Engl J Med 2017;377:829-38.
[5] Shaw A, et al. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. N Engl J Med.2020;383:2108-29.
[6] Hurwitz J, et al. Cost-Effectiveness of PD-L1 Testing in Non-Small Cell Lung Cancer (NSCLC) Using In Vitro Diagnostic (IVD) Versus Laboratory-Developed Test (LDT). Oncology and Therapy, May 2023.

Published by:
Roche Diagnostics (Thailand) Co., Ltd.
18-19th Floor, Rasa Tower Building
555 Paholyothin Rd, Chatuchak, Bangkok 10900 Thailand

MC-TH-01155
AN 6800234
Valid Till 25/02/2027